Abaloparatide Builds More Bone Than Teriparatide at the Hip in Postmenopausal Women

Systematic review and meta-analysis searching Medline, Embase, Web of Science, Cochrane, and ClinicalTrials.gov through September 2022. Only randomized controlled trials with direct head-to-head comparisons of abaloparatide vs teriparatide were included. Evidence quality was assessed using the GRADE framework. Outcomes included BMD change from baseline and adverse event rates.

For the millions of postmenopausal women with osteoporosis, choosing between the two available bone-building peptide drugs has been difficult due to limited head-to-head data. This meta-analysis provides the most comprehensive comparison to date, suggesting abaloparatide may offer an edge at the hip — the most clinically important fracture site — while also being associated with less hypercalcemia, a meaningful safety advantage.

Both abaloparatide and teriparatide are peptide analogs related to parathyroid hormone that stimulate bone formation — a fundamentally different approach from antiresorptive drugs like bisphosphonates that only slow bone loss. This meta-analysis helps clinicians differentiate between the two anabolic options, particularly for patients at high risk of hip fractures where abaloparatide's advantage appears most pronounced.

Only four studies met inclusion criteria, all from manufacturer-sponsored trials, which introduces potential bias. Fracture data was insufficient for analysis — and fracture prevention, not BMD alone, is the ultimate clinical outcome. The meta-analysis was limited to postmenopausal women, so results may not apply to men or premenopausal osteoporosis. Most comparisons relied on post hoc analyses of RCTs rather than pre-specified head-to-head designs.